Treatment with the recombinant oncolytic poliovirus PVSRIPO elicited sustained a 2- and 3-year overall survival (OS) rate of 21% (95% CI, 11%-33%) for patients with recurrent grade IV malignant glioblastoma.
Original Article: Oncolytic Poliovirus Shows Sustained Survival Rates for Recurrent GBM